Iktos, announced a research collaboration with Zealand Pharma A/S to co-develop generative and predictive AI technologies for peptide drug design. Under the agreement, Zealand will contribute its expertise in peptide drug discovery to Iktos' generative modelling technologies and expertise in machine learning and AI.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
697.5 DKK | 0.00% | +1.68% | +86.90% |
Mar. 14 | Global markets live: Robinhood, Dollar General, KKR, Boeing, Oracle... | |
Mar. 13 | Zealand Pharma A/S Announces Board Changes | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+86.90% | 6.34B | |
+1.10% | 105B | |
+9.29% | 104B | |
-3.00% | 22.09B | |
-11.89% | 21.98B | |
-26.59% | 20.17B | |
-5.20% | 19.49B | |
-6.58% | 17.75B | |
+5.83% | 13.84B | |
+7.46% | 11.64B |
- Stock
- Equities
- Stock Zealand Pharma A/S - Nasdaq Copenhagen
- News Zealand Pharma A/S
- Iktos and Zealand Pharma A/S to Develop Artificial Intelligence Technology for Peptide Drug Design